Vaxcyte (PCVX) is a publicly traded Healthcare sector company. As of May 20, 2026, PCVX trades at $47.17 with a market cap of $6.99B and a P/E ratio of -12.31. PCVX moved -3.28% today. Year to date, PCVX is +2.48%; over the trailing twelve months it is +28.99%. Its 52-week range spans $27.66 to $118.62. Analyst consensus is strong buy with an average price target of $109.43. Rallies surfaces PCVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Vaxcyte Raises $2.7B Cash, Completes Enrollment in Three Phase 3 VAX-31 Trials: Vaxcyte completed enrollment of 6,191 adults in Phase 3 OPUS trials evaluating its VAX-31 pneumococcal conjugate vaccine, with topline safety and immunogenicity data due Q4 2026 for OPUS-1 and H1 2027 for OPUS-2 and OPUS-3. It holds $2.7 billion in cash and expects to initiate a Phase 1 VAX-A1 study mid-2026.
| Metric | Value |
|---|---|
| Price | $47.17 |
| Market Cap | $6.99B |
| P/E Ratio | -12.31 |
| EPS | $-3.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $118.62 |
| 52-Week Low | $27.66 |
| Volume | 3.93M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-463.93M |
| Gross Margin | 0.00% |
8 analysts cover PCVX: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $109.43.